[Studies on the treatment of male infertility with kallikrein].
70 subfertile patients were given oral (600 K.U./daily) or parenteral (3 X 40 K.U./weekly) Kallikrein-treatment for seven weeks. Statistical evaluation of the findings yielded positive changes (level of significance alpha less than 1%) in cases of reduced spermatozoa count, motility, and morphology. In respect to clinical diagnosis the most satisfactory effects were achieved in cases of the vegetative congestion syndrome, which includes functional disturbances of the epididymis, the testicular outlet of spermatozoa, and the last phase of spermatid maturation. In cases of testis parenchyma disorders a true effect was not noted. Probably Kallikrein influences the function of epididymis and SERTOLIcells, which can be concluded by the results of the spermatological examinations in the course of the treatment. Because of the short duration of treatment, it is impossible to decide, wether the proliferation of the germinal epithelium is increased as well. A negative effect was observed in cases of chronic inflammations of the genital tract, the inflammatory process being activated by Kallikrein, which was not unexpected.
D000284:Administration, Oral; D006801:Humans; D007248:Infertility, Male / Q000188:drug therapy*; D007273:Injections, Intramuscular; D007610:Kallikreins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D013081:Sperm Motility / Q000187:drug effects; D013091:Spermatogenesis / Q000187:drug effects
D007610:Kallikreins
Untersuchungen zur Kallikrein-Behandlung männlicher Fertilitätsstörungen